Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 23:13:1017129.
doi: 10.3389/fphar.2022.1017129. eCollection 2022.

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Nasser M Alorfi  1
Affiliations
Review

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Nasser M Alorfi. Front Pharmacol. .

Abstract

Background: Fibromyalgia is a chronic neurological condition characterized by widespread pain. The effectiveness of current pharmacological treatments is limited. However, several medications have been approved for phase IV trials in order to evaluate them. Aim: To identify and provide details of drugs that have been tested in completed phase IV clinical trials for fibromyalgia management in adults, including the primary endpoints and treatment outcomes. This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology. Method: Publicly available and relevant phase IV trials registered at ClinicalTrials.gov were analyzed. The uses of the trialed drugs for fibromyalgia were reviewed. Results: As of 8 August 2022, a total of 1,263 phase IV clinical trials were identified, of which 121 were related to fibromyalgia. From these, 10 clinical trials met the inclusion criteria for the current study. The drugs used in phase IV trials are milnacipran, duloxetine, pregabalin, a combination of tramadol and acetaminophen, and armodafinil. The effectiveness of the current pharmacological treatments is apparently limited. Conclusion: Due to its complexity and association with other functional pain syndromes, treatment options for fibromyalgia only are limited and they are designed to alleviate the symptoms rather than to alter the pathological pathway of the condition itself. Pain management specialists have numerous pharmacologic options available for the management of fibromyalgia.

Keywords: clinical trials; fibromyalgia; neuroscience; pain; phase IV.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abeles A. M., Pillinger M. H., Solitar B. M., Abeles M. (2007). Narrative review: The pathophysiology of fibromyalgia. Ann. Intern. Med. 146, 726–734. 10.7326/0003-4819-146-10-200705150-00006 - DOI - PubMed
    1. Ablin J., Fitzcharles M. A., Buskila D., Shir Y., Sommer C., Häuser W. (2013). Treatment of fibromyalgia syndrome: Recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence-Based Complementary Altern. Med. 2013, 1–7. 10.1155/2013/485272 - DOI - PMC - PubMed
    1. Alles S. R. A., Cain S. M., Snutch T. P. (2020). Pregabalin as a pain therapeutic: Beyond calcium channels. Front. Cell. Neurosci. 14, 83. 10.3389/FNCEL.2020.00083/BIBTEX - DOI - PMC - PubMed
    1. Aman M. M., Jason Yong R., Kaye A. D., Urman R. D. (2018). Evidence-Based non-pharmacological therapies for fibromyalgia. Curr. Pain Headache Rep. 22, 33. 10.1007/S11916-018-0688-2 - DOI - PubMed
    1. Amsterdam D., Buskila D. (2021). Etiology and triggers in the development of fibromyalgia. Fibromyalgia Syndr., 17–31. 10.1007/978-3-030-78638-0_3 - DOI